Does xgeva cause jaw bone problems?

Does Xgeva cause jaw problems?

Xgeva (denosumab) is known to cause osteonecrosis of the jaw, a serious condition where jawbone tissue dies. This occurs in patients receiving denosumab for bone metastases or giant cell tumor of bone. The risk rises with dental procedures, poor oral hygiene, or prolonged use.

How does jaw necrosis develop?

Denosumab inhibits RANKL, blocking osteoclasts—the cells responsible for bone remodeling. Without active osteoclasts, micro-damage accumulates in the jaw, especially after tooth extractions or oral surgery. The high-turnover rate of jawbone makes it particularly vulnerable.

What is the incidence rate?

Studies show osteonecrosis of the jaw occurs in 1–2% of patients taking Xgeva for cancer-related bone loss. Incidence increases with time on treatment and number of doses. The manufacturer recommends a dental exam before starting Xgeva and avoiding invasive dental procedures during treatment.

What happens if you develop jaw problems?

Patients who entwickeln osteonecrosis of the jaw may experience pain, swelling, exposed bone, loose teeth, or infection. Management includes stopping Xgeva temporarily, antibiotics, antibacterial mouthwashes, and surgical debridement in severe cases. Recovery may take months.

What alternatives exist if jaw risk is high?

Alternatives include zoledronic acid or pamidronate, bisphosphonates that similarly affect bone metabolism and carry a comparable ONJ risk. Some patients can switch to teriparatide or romosozumab for osteoporosis, but these are not suitable for cancer-related bone loss.

When does Xgeva patent expire?

Xgeva's primary U.S. patent expires in 2025. Biosimilars may enter the market once patent barriers fall. DrugPatentWatch.com tracks these dates and provides details on full patent family expirations and underlying patents.